US biosimilar market in 2023

Expected launches and uptake are likely to increase overall spending on biosimilars significantly to $20–$49Bn in 2027 and cumulative sales of ...

2023 U.S. Generic and Biosimilar Medicines Savings Report

Featuring data reported by IQVIA, the 2023 U.S. Generic & Biosimilar Medicines Savings Report reveals generic and biosimilar drugs generated a record $408 ...

The State of Biosimilars in 2023

biosimilars had a pathway to enter the U.S. market. While there have been challenges over this time, the U.S. biosimilar market has come a long way and has ...

Generic and Biosimilar Medicines Save $445 Billion in 2023

AAM's annual savings report reveals that the use of Food and Drug Administration (FDA) approved generic and biosimilar medicines created $445 ...

Now Trending: Biosimilars - IQVIA

Celltrion's Yuflygma received FDA approval in June 2023 as the 9th adalimumab biosimilar (i.e., Humira biosimilar) and is expected to launch in ...

AAM Report: Generics and Biosimilars Savings Reach $445 Billion ...

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the ...

Th U.S. market now has 40 FDA-approved biosimilar products with 25 commercially available, including four products with an interchangeable ...

To date, there have been 41 approvals and 30 launches in the U.S. biosimilar market.biosimilar ... Podcast: How 2023 will shape the US Biosimilar ...

The laws establishing the US biosimilar approval pathway were passed in 2010, but the years 2023 and 2024 can be pivotal for the biosimilar market.

There are currently 27 biosimilars on the market competing against. 10 brand biologics, with at least seven more biosimilars anticipated to launch in 2023.1 ...

News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big “deluge” in biosimilars, ...

The first filgrastim biosimilar to launch has been the US market leader since Q3 2018. ... As of Q3 2023, Infliximab biosimilar market share has reached 54%.

What 2023 Has Taught Us About Biosimilar Adoption

The complexities of the US health care market, low awareness of biosimilars, and a reluctance by health care practitioners (HCPs) and patients ...

North America dominated the market with the largest revenue share of 41.0% in 2023. driven by the expiration of patents for established biologic ...

A New Chapter: How 2023 Will Shape the US Biosimilar Space for ...

As 2023 comes to a close, we look back on some of the major advancements from the past year, from the long-awaited market introduction of ...

SAMSUNG BIOEPIS - Biosimilar Market Report

fundamental for the sustainable growth of the US biosimilar market. To ... As of April 2023, the FDA has approved a total of 40 biosimilars across 11 ...

Biosimilar Product Information | FDA

... biosimilars to market. The approval of biosimilar products can ... December 2023, Avastin (bevacizumab), Avzivi Information. Wezlana ...

The 2024 U.S. Generic & Biosimilar Medicines Savings Report shows savings will continue to grow—with $445 billion saved in 2023, alone. Press Releases.

IQVIA Predicts US Spending on Biosimilars Will Reach $129 Billion ...

Anticipated launches and uptake of biosimilars are predicted to increase spending to $129 billion and savings by $180 billion over the next 5 years.

On January 30, 2024, life sciences attorneys Rae Crisler, Martina Hufnal, and Philip Chen will provide a comprehensive look at the US biosimilars field in 2023.